LEKTI-Grafted Sunflower Trypsin Inhibitor: A Potential Therapeutic for Skin Diseases

Kallikrein 5 (KLK5) is a serine protease expressed in the outer skin layers, where it regulates the barrier function by cleaving desmosomal proteins. Elevated KLK5 causes excessive proteolysis, leading to corneocyte overdesquamation and barrier compromise. Increased KLK5 activity has been linked to atopic dermatitis (AD), a chronic inflammatory disease affecting up to 20% of children, highlighting the need for therapies that restore barrier integrity. While many serine protease inhibitors have been developed, most lack KLK5 selectivity. To address this, novel analogues of the sunflower trypsin inhibitor were designed and evaluated. Lead 7 emerged as a potent (IC50 = 14 ± 4 nM; Ki = 11 nM) selective KLK5 inhibitor. In keratinocytes from a Netherton syndrome patient, lead 7 significantly reduced the KLK5 activity and improved epithelial barrier integrity, as shown by transepithelial electrical resistance. These findings suggest lead 7 as a potential therapy for AD and other conditions with elevated KLK5 activity.

• Publication year

  2025

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2025-11-10

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.1021/acs.jmedchem.5c01912PMID 41215618PMCID 12670400
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative analyses of Netherton syndrome patients and Spink5 conditional knock-out mice uncover disease-relevant pathways

  2024cited by this paper
• Molecular Peptide Grafting as a Tool to Create Novel Protein Therapeutics

  2023cited by this paper
• Therapeutic peptides: current applications and future directions

  2022cited by this paper
• Peptide-based drug discovery: Current status and recent advances.

  2022cited by this paper
• A potent and selective Kallikrein-5 inhibitor delivers high pharmacological activity in Netherton Syndrome patient skin.

  2021cited by this paper
• Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases

  2019cited by this paper
• Amino Acid Scanning at P5' within the Bowman-Birk Inhibitory Loop Reveals Specificity Trends for Diverse Serine Proteases.

  2019cited by this paper
• Kallikreins: Essential epidermal messengers for regulation of the skin microenvironment during homeostasis, repair and disease

  2019cited by this paper
• The skin as a target for prevention of the atopic march.

  2018cited by this paper
• Immunologic, microbial, and epithelial interactions in atopic dermatitis.

  2018cited by this paper
• Profiling system for skin kallikrein proteolysis applied in gene-deficient mouse models

  2018cited by this paper
• Immortalized N/TERT keratinocytes as an alternative cell source in 3D human epidermal models

  2017cited by this paper
• Protein and Peptide Biopharmaceuticals: An Overview.

  2017cited by this paper
• Therapeutic peptides: Historical perspectives, current development trends, and future directions.

  2017cited by this paper
• Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold – A Potential Therapeutic Intervention for Skin Diseases

  2016cited by this paper
• Inhibition of Kallikrein‐Related Peptidases 7 and 5 by Grafting Serpin Reactive‐Center Loop Sequences onto Sunflower Trypsin Inhibitor‐1 (SFTI‐1)

  2016cited by this paper
• Skin pH is the Master Switch of Kallikrein 5-Mediated Skin Barrier Destruction in a Murine Atopic Dermatitis Model.

  2015cited by this paper
• Sunflower trypsin inhibitor (SFTI-1) analogues of synthetic and biological origin via N→S acyl transfer: potential inhibitors of human Kallikrein-5 (KLK5)

  2014cited by this paper
• High-affinity Cyclic Peptide Matriptase Inhibitors*

  2013cited by this paper
• Future directions for peptide therapeutics development.

  2013cited by this paper
• The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.

  2012cited by this paper
• A Review of its Pharmacology and Therapeutic Efficacy in Reducing Blood Loss Associated with Cardiac Surgery

  2012cited by this paper
• Epidermal Barrier in Atopic Dermatitis

  2011cited by this paper
• Increased stratum corneum serine protease activity in acute eczematous atopic skin

  2009cited by this paper
• Kallikrein 5 induces atopic dermatitis–like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome

  2009cited by this paper
• Human Kallikrein-related Peptidase 14 (KLK14) Is a New Activator Component of the KLK Proteolytic Cascade

  2008cited by this paper
• Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients

  2007cited by this paper
• Kallikrein 8 Is Involved in Skin Desquamation in Cooperation with Other Kallikreins*

  2007cited by this paper
• Expression and Functional Characterization of the Cancer-related Serine Protease, Human Tissue Kallikrein 14*

  2007cited by this paper
• Distribution of 15 human kallikreins in tissues and biological fluids.

  2007cited by this paper
• The Absolute Structural Requirement for a Proline in the P3′-position of Bowman-Birk Protease Inhibitors Is Surmounted in the Minimized SFTI-1 Scaffold*

  2006cited by this paper
• A Potential Role for Multiple Tissue Kallikrein Serine Proteases in Epidermal Desquamation*

  2006cited by this paper
• Specificity Profiling of Seven Human Tissue Kallikreins Reveals Individual Subsite Preferences*

  2006cited by this paper
• A proteolytic cascade of kallikreins in the stratum corneum.

  2005cited by this paper
• Solution Structure of a Novel C2-Symmetrical Bifunctional Bicyclic Inhibitor Based on SFTI-1

  2005cited by this paper
• Complete substitutional analysis of a sunflower trypsin inhibitor with different serine proteases.

  2005cited by this paper
• Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases

  2005cited by this paper
• Design, synthesis and analysis of novel bicyclic and bifunctional protease inhibitors.

  2004influential reference
• Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7.

  2004cited by this paper
• Association between polymorphisms in the SPINK5 gene and atopic dermatitis in the Japanese

  2003cited by this paper
• Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages.

  2003cited by this paper
• Gene polymorphism in Netherton and common atopic disease

  2001cited by this paper
• Human Keratinocytes That Express hTERT and Also Bypass a p16INK4a-Enforced Mechanism That Limits Life Span Become Immortal yet Retain Normal Growth and Differentiation Characteristics

  2000cited by this paper
• High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds.

  1999cited by this paper
• Interscaffolding additivity: binding of P1 variants of bovine pancreatic trypsin inhibitor to four serine proteases.

  1999cited by this paper
• LEKTI, a Novel 15-Domain Type of Human Serine Proteinase Inhibitor*

  1999cited by this paper
• Binding of amino acid side-chains to S1 cavities of serine proteinases.

  1997cited by this paper
• Cysteinyl proteinases and their selective inactivation.

  1990cited by this paper
• Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase.

  1977cited by this paper
• These authors contributed equally to this work. Abbreviations BIA: Biomolecular Interaction Analysis CHO: Chinese Hamster Ovary

  year unknowncited by this paper

• No citing papers are available for this paper.